|  | DM | No DM | ||||
---|---|---|---|---|---|---|---|
Variable | Overall (N = 4380) | UA > 7 (n = 1174) | UA < 7 (n = 602) | p-value | UA > 7 (n = 1737) | UA < 7 (n = 867) | p-value |
Age (y) | 71 ± 14.8 | 71 ± 12.2 | 73 ± 11.8 | 0.001a | 70 ± 16.8 | 72 ± 15.3 | < 0.001a |
Male sex | 2747(62.7) | 741(63.1) | 352(58.5) | 0.057b | 1142(65.7) | 512(59.1) | < 0.001b |
CKD stage |  |  |  | < 0.001b |  |  | < 0.001b |
  3 | 2076(47.4) | 461(39.3) | 323(53.7) |  | 803(46.2) | 489(56.4) |  |
  4 | 1364(31.1) | 414(35.3) | 200(33.2) |  | 530(30.5) | 220(25.4) |  |
  5 | 940(21.5) | 299(25.5) | 79(13.1) |  | 404(23.3) | 158(18.2) |  |
Ever smoke | 1688(38.5) | 509(43.4) | 213(35.4) | 0.001b | 670(38.6) | 296(34.1) | 0.027b |
Previous CAD | 225(5.1) | 86(7.3) | 31(5.1) | 0.08b | 69(4.0) | 39(4.5) | 0.526b |
Baseline SBP (mmHg) | 134 ± 18.7 | 138 ± 19.5 | 135 ± 18.1 | 0.013a | 133 ± 18.5 | 132 ± 17.9 | 0.40a |
1 year mean SBP (mmHg) | 134 ± 16.1 | 137 ± 16.4 | 135 ± 15.6 | 0.014a | 133 ± 16.1 | 131 ± 15.3 | 0.118a |
Baseline DBP (mmHg) | 75 ± 11.1 | 75 ± 10.8 | 74 ± 10.3 | 0.043a | 75 ± 11.4 | 75 ± 11.2 | 0.34a |
1 year mean DBP (mmHg) | 74 ± 9.5 | 75 ± 8.9 | 74 ± 8.9 | 0.116a | 75 ± 10.0 | 74 ± 9.4 | 0.092a |
Baseline UA (mg/dl) | 8.1 ± 2.5 | 9.2 ± 3.1 | 6.0 ± 1.1 | < 0.001a | 9.1 ± 1.8 | 6.0 ± 1.1 | < 0.001a |
1 year mean UA (mg/dl) | 8.0 ± 2.1 | 9.1 ± 2.1 | 5.9 ± 0.9 | < 0.001a | 8.9 ± 1.5 | 5.9 ± 0.9 | < 0.001a |
Baseline cholesterol (mmol/l) | 185.2 ± 51.4 | 183.5 ± 53.0 | 180.1 ± 50.8 | 0.214a | 187.9 ± 50.1 | 185.7 ± 51.9 | 0.325a |
Statin usage | 1522(34.7) | 544(46.3) | 279(46.3) | 0.997b | 473(27.2) | 226(26.1) | 0.528b |
ACEi/ARB usage | 2540(58.0) | 802(68.3) | 401(66.6) | 0.468b | 916(52.7) | 421(48.6) | 0.045b |
Uric acid-lowering drugs | 1228 (28.0) | 306 (26.1) | 107 (17.8) | < 0.0001 | 599 (34.5) | 216 (24.9) | < 0.0001 |